1381930-17-1
1381930-17-1 structure
- Name: TBK1/IKKε-IN-4
- Chemical Name: N-{3,4-Dimethoxy-5-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine
- CAS Number: 1381930-17-1
- Molecular Formula: C28H35N7O4
- Molecular Weight: 533.622
- Catalog: Signaling Pathways NF-κB IKK
- Create Date: 2020-01-12 00:32:50
- Modify Date: 2024-01-11 18:36:56
-
TBK1-IKKε inhibitor II is a potent, selective dual inhibitor of TBK1/IKKε with IC50 of 13 nM/59 nM, respectively; displays 100- to 1000-fold less activity against other tested protein kinases including PDK1, PI3K family members and mTOR; inhibits LPS-induced expression of IFNβ (IC50=62 nM), and the IFNβ target genes IP10 (IC50=78 nM) and Mx1 (IC50=20 nM); effectively blocks TLR3-dependent IRF3 nuclear translocation in cells with IC50<100 nM.
| Name | N-{3,4-Dimethoxy-5-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine |
|---|---|
| Synonyms |
1H-Pyrazolo[3,4-d]pyrimidin-6-amine, N-[3,4-dimethoxy-5-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-1-(4-methoxyphenyl)-
N-{3,4-Dimethoxy-5-[3-(4-methyl-1-piperazinyl)propoxy]phenyl}-1-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine |
| Description | TBK1-IKKε inhibitor II is a potent, selective dual inhibitor of TBK1/IKKε with IC50 of 13 nM/59 nM, respectively; displays 100- to 1000-fold less activity against other tested protein kinases including PDK1, PI3K family members and mTOR; inhibits LPS-induced expression of IFNβ (IC50=62 nM), and the IFNβ target genes IP10 (IC50=78 nM) and Mx1 (IC50=20 nM); effectively blocks TLR3-dependent IRF3 nuclear translocation in cells with IC50<100 nM. |
|---|---|
| Related Catalog | |
| Target |
IKKε:59 nM (IC50) TBK1:13 nM (IC50) |
| In Vitro | TBK1/IKKε-IN-4 (Compound II; 96 hours; A549 andHCC44 cells) treatmentdisplays selective toxicity in TBK1-dependent cancer cell lines (IC50 of ~ 4.2 µM for H441 cells and IC50 of ~0.4 µM for A549 cells)[1]. TBK1/IKKε-IN-4 (Compound II; 0-2 µM; 30 minutes; HCC44 cells) treatment inhibits the AKT activity[1]. TBK1/IKKε-IN-4 (Compound II) inhibits LPS-induced expression of IFNβ (IC50 =62 nM), and the IFNβ target genes IP10 (IC50 =78 nM) and Mx1 (IC50=20 nM). TBK1/IKKε-IN-4 effectively blocksTLR3-dependent IRF3 nuclear translocation in cells with an IC50 under 100 nM, but does not impair TNFR1-dependent p65 NFκB nuclear translocation with doses as high as 20 µM[1]. Western Blot Analysis[1] Cell Line: HCC44 cells Concentration: 0 µM, 0.5 µM, 1 µM, 2 µM Incubation Time: 30 minutes Result: Was sufficient to blunt baseline AKT activity. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 668.1±65.0 °C at 760 mmHg |
| Molecular Formula | C28H35N7O4 |
| Molecular Weight | 533.622 |
| Flash Point | 357.9±34.3 °C |
| Exact Mass | 533.275024 |
| LogP | 2.85 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.633 |